NR3C2 and hydrops fetalis: Finally, the FINALITY-HF trial (NCT06033950) addresses a significant unmet need by investigating finerenone in patients with HFrEF who are intolerant to or ineligible for steroidal MRAs, potentially offering a solution for those currently excluded from mineralocorticoid receptor antagonism.